Last reviewed · How we verify
RHENIUM RE-186 OBISBEMEDA
At a glance
| Generic name | RHENIUM RE-186 OBISBEMEDA |
|---|---|
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases (PHASE1)
- Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RHENIUM RE-186 OBISBEMEDA CI brief — competitive landscape report
- RHENIUM RE-186 OBISBEMEDA updates RSS · CI watch RSS